Mission Therapeutics has agreed to divest its phase 2‑ready acute kidney injury candidate MTX652 to Australian renal ...

First patient randomised as study advances novel pan phosphate transporter inhibitor R1 Therapeutics has randomized the first ...

Nouscom will present new phase 1b/2 data on its off‑the‑shelf cancer immunotherapy NOUS‑209 at the European Society for ...

ViiV Healthcare will present a broad range of clinical and real-world data at AIDS 2026, highlighting progress across its integrase strand transfer inhibitor portfolio, including long-acting medicines ...

Jasper Therapeutics has completed its all‑stock acquisition of Kira Pharmaceuticals, creating a combined business focused on ...

Ardena has appointed Ariane de Ganck as Chief Scientific Officer, reinforcing its focus on scientific excellence across its ...

The Scottish Medicines Consortium has recommended Astellas’s VEOZA (fezolinetant) 45 mg once daily for the treatment of ...

EpilepsyGTx has partnered with ClearPoint Neuro to enable targeted delivery of its lead gene therapy candidate, EPY201, ahead ...

An update on the first clinical trial evaluating a pluripotent stem cell‑derived neural stem cell therapy for Huntington’s ...

Merck has announced that the European Commission has approved an update to the Erbitux (cetuximab) EU label, extending its ...

Can AI deliver the productivity gains pharma needs?

Braun has appointed Sophie Spencer as Social Value & ESG Specialist, recognising her rapid impact since joining the company ...